Randomised double blind controlled clinical trial of intranasal budesonide in treatment of hay fever.
The effectiveness of budesonide, a new non-halogenated glucocorticoid administered by nasal inhaler, was evaluated in a double blind comparison with placebo in patients presenting with hay fever. Patients were supplied with antihistamine tablets and eye drops for use when they considered that their symptoms were inadequately controlled by their inhaler. Patients recorded the severity of their symptoms in a daily diary card and visited their general practitioner for assessment weekly for four weeks. All nasal symptoms of hay fever were appreciably reduced in the group taking budesonide and, although their eye symptoms were more severe than in the group taking placebo, they did not use appreciably more eye drops than the latter. The placebo group used appreciably more antihistamine tablets than those in the budesonide group. No patients were withdrawn from the budesonide group because of treatment failure or unacceptable side effects. The results suggest that budesonide is an acceptable and effective treatment for the nasal symptoms of hay fever.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D019819:Budesonide; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide